Bristol-Myers Squibb Foundation Announces Collaboration with World Health Organization's Stop TB Department

Bristol-Myers SquibbThe Bristol-Myers Squibb Foundation today announced a collaboration with the World Health Organization's (WHO) Stop TB Department for a two-year pilot initiative to strengthen community based prevention, care and control of tuberculosis (TB) including co-infection with HIV in South Africa, Tanzania, Kenya, Ethiopia and Democratic Republic of the Congo. These five countries collectively represented more than 13 percent of global TB and more than one-third of the TB/HIV co-infection burden in 2009.

The initiative is expected to be a catalyst in boosting the meaningful engagement of non-governmental and community organizations, a key objective in the WHO's Stop TB strategy, and will draw on technical assistance through community care experts from the Bristol-Myers Squibb Foundation's SECURE THE FUTURE® program.

"Bristol-Myers Squibb's commitment to help communities prevail over serious diseases is embodied in our Foundation's mission to address health disparities and empower communities," said Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb. "The hallmark of the Bristol-Myers Squibb Foundation's SECURE THE FUTURE® program is strengthening capacity in local communities. Our work in TB and HIV co-infection has demonstrated the positive impact that community support can have on tracking, follow-up of results and treatment for infected individuals."

The WHO will use its facilitation and brokering role with National TB and AIDS Control Programs to scale up community TB care in the five countries through strengthened engagement of non-governmental (NGOs) and community based organizations. WHO will promote the development of policies and programs that will enable greater involvement of NGOs and civil society organizations in TB community care and the creation of a more cost-effective and sustainable TB response.

This initiative offers a unique opportunity in partnership with SECURE THE FUTURE® to enhance the earlier detection of people with TB to ensure they are treated successfully, and have better access to TB services, especially in HIV prevalent settings. TB services will be strengthened and improved by embracing the advantages that NGOs can bring, such as access to remote areas and a better understanding of local needs, especially among vulnerable groups.

About the Bristol-Myers Squibb Foundation
The Bristol-Myers Squibb Foundation is an independent 501(c)(3) charitable organization whose mission is to reduce health disparities and improve health outcomes around the world for patients disproportionately affected by serious disease.

SECURE THE FUTURE® is the flag ship initiative of the Bristol-Myers Squibb Foundation. Since 1999, Bristol-Myers Squibb and the Bristol-Myers Squibb Foundation have committed $160 million to develop sustainable solutions for vulnerable populations, including women and children infected and affected by HIV/AIDS in Africa. Since its inception, the initiative has provided support for more than 240 projects focused on community education, outreach, medical care and research in 19 countries.

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases.

Most Popular Now

Top 20 breaking World Pharma News of 2017

We are proud to announce the top 20 most popular breaking World Pharma News from 2017. Have a wonderful 2018 new(s) year filled with health, happiness, and spectacular su...

Novartis advances head-to-head superiority trials …

Novartis announced today the initiation of SURPASS, a head-to-head clinical trial of Cosentyx® (secukinumab) versus proposed biosimilar adalimumab** in ankylosing spondyl...

Diabetes drug 'significantly reverses memory loss…

A drug developed for diabetes could be used to treat Alzheimer's after scientists found it "significantly reversed memory loss" in mice through a triple method of action...

Sandoz regulatory submission for proposed biosimil…

Sandoz, a Novartis division and the global leader in biosimilar medicines, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics Licen...

Zika remains a research and public health challeng…

Since 2016, when Zika was declared by the World Health Organization as a public health emergency of international concern, the virus has become established in more than 8...

Try exercise to improve memory, thinking

For patients with mild cognitive impairment, don't be surprised if your health care provider prescribes exercise rather than medication. A new guideline for medical pract...

New research paper shows that AstraZeneca has achi…

In a research paper published today by Nature Reviews Drug Discovery(1), AstraZeneca's IMED Biotech Unit documents a more than four-fold improvement in R&D productivity f...

Dirt-dwelling microbe produces potential anti-mela…

A type of soil-dwelling bacterium produces molecules that induce death in melanoma cells, research at Oregon State University shows. The molecule is a secondary metabolit...

Novartis Kisqali® received FDA Breakthrough Therap…

Novartis today announced Kisqali® (ribociclib) received US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based treatment of pr...

FDA approves first treatment for breast cancer wit…

The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast can...

Berry gives boost to cervical cancer therapy

According to the Centers for Disease Control and Prevention, approximately 12,000 women in the United States are diagnosed with cervical cancer each year. One of the most...

Novartis appoints Elizabeth Barrett as Oncology He…

Novartis announced today that Elizabeth (Liz) Barrett, currently Global President Oncology at Pfizer, Inc., has been appointed CEO Novartis Oncology and a member of the E...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]